GLYCOGENE
Your trusted partner for Nucleic Acid and Carbohydrate raw materials
GLYCOGENE
Products
To provide customers with customized products and services
-- Has cooperated with a number of domestic and international pharmaceutical and chemical companies
Glycogene was founded and led by world-leading synthetic chemistry scholar, who has over 30 years of extensive experience in biological and chemical synthesis. Glycogene has more than 200 employees, including 12 doctors and more than 40 masters. By integrating multiple synthetic technologies such as biosynthesis, fermentation and organic synthesis technologies, Glycogene focuse on offering high quality and cost-effective carbohydrates, nucleosides, nucleotides, phosphoramidites and protein structures. Also, we can provide custom synthesis services as needed. Glycogne has served hundreds of worldwide Pharma and Biotech.
Glycogene headquartered in Wuhan Optics Valley and has subsidiary located in North Carolina. Glycogene also has R & D centers and pilot-scale modern laboratories in Qingdao and Shenzhen, manufacture in Panjin.
WHO ARE WE？
About GLYCOGENE
Glycogene was founded in April 2019
More than 250 Employee
The company covers over 17,500 square meters of corporate space
The company has been awarded 10 regional and international certificates
Facilities
Technologies breakthrough in RNA field
2006: Nobel Prize for RNA Interference (RNAi) Mechanism Laid the Theoretical Foundation for Oligonucleotide Drugs
2006: Nobel Prize for RNA Interference (RNAi) Mechanism Laid the Theoretical Foundation for Oligonucleotide Drugs
2005-2010: Elucidation of Nucleobase Modification and Immune Interaction Resolved the Early Severe Immunotoxicity of Exogenous mRNA
2005-2010: Elucidation of Nucleobase Modification and Immune Interaction Resolved the Early Severe Immunotoxicity of Exogenous mRNA
2014: Birth of GalNAc Liver-Targeted Delivery Technology — A Breakthrough for Oligonucleotide Industrialization
2014: Birth of GalNAc Liver-Targeted Delivery Technology — A Breakthrough for Oligonucleotide Industrialization
2018: Global First siRNA Drug Onpattro Approved — Nucleic Acid Drugs Officially Enter Commercialization
2018: Global First siRNA Drug Onpattro Approved — Nucleic Acid Drugs Officially Enter Commercialization
2020: Global Emergency Approval of mRNA COVID-19 Vaccines — Nucleic Acid Technology Achieved Mass Popularization
2020: Global Emergency Approval of mRNA COVID-19 Vaccines — Nucleic Acid Technology Achieved Mass Popularization
Technologies breakthrough in glycoscience field
1990s: Chemical enzymatic glycan synthesis.
Upon decades of work by researchers such as Yukio Ito, Qihui Weng, Peter Seeberger, and Peng George Wang, chemical enzymatic glycan synthesi has moved from the laboratory to 'glycan factories'—where the combination of automation and AI-assisted synthesis will fundamentally rewrite the economic model for glycan acquisition.
2000s：Synthetic biology of glycans.
With the industrialization of HMOs, showcases the significant commercial feasibility of precisely fermenting glycan compounds. We are also actively expanding our presence in the synthetic biology industry and have scaled up the production of synthetic biology sugar products such as L-fucose and ManNAc.
2010s：Antibody-drug conjugate (ADC) glycoconjugation technology.
Glycans can serve as anchors for precise drug delivery. We has established an ADC conjugation platform based on glycan remodeling, offering glycan remodeling enzymes (glycosidases + glycosyltransferases) and copper-free click chemistry connection technologies.
2022：Click Chemistry
The awarding of the 2022 Nobel Prize in Chemistry to click chemistry and bioorthogonal chemistry marks a Nobel-level tool revolution in glycoscience, promoted all-round breakthroughs of glycobiology in aqueous-phase reaction, precise synthesis, in vivo labeling and drug development.
Blog Center
Working Together, Chasing the Light | Tangzhi Pharmaceutical 2025 New Year Gala
As the year turns and a new chapter unfolds, we look back on 2024, a year of progress and achievement for Tangzhi. This year, we held grand annual meetings in Wuhan, Qingdao, and Panjin, celebrating our successes together. Wuhan, as the headquarters of Tangzhi Pharmaceutical, holds our initial aspirations and dreams. In 2024, we achieved remarkable results. The company was successfully selected for Wuhan's "Backbone High-tech Enterprise Gazelle Plan" and recognized as a "Potential Unicorn" enterprise in the East Lake High-tech Development Zone, a "2024 Deloitte China High-Tech High-Growth 50 Strong" company, and a "2024 Deloitte Guanggu High-Tech High-Growth Top 20" company. Over the past year, Tangzhi Pharmaceutical has continued to focus on technological innovation and product development, resulting in steady revenue growth. At the Wuhan annual meeting, in his opening address, Chairman Wang Peng reviewed the outstanding achievements we made in technological innovation and market expansion, thanked every employee for their hard work, and looked forward to the new year, where we will continue to cultivate the fields of sugar and nucleic acids, providing even better products and services to global customers.
2025-01-27
Recently, the "2024 Deloitte China Technology Fast 50" (hereinafter referred to as "China 50") was announced. Tangzhi Pharmaceutical, with its outstanding performance and rapid growth in the fields of sugar and nucleic acids, was honored to be on the list, ranking 15th with a revenue growth rate exceeding 690%! This honor is not only an affirmation of Tangzhi Pharmaceutical's innovative strength in the fields of sugar and nucleic acids, but also a commendation for its high-speed growth in a difficult environment. The Deloitte China Technology Fast 50 program has always been regarded as a "benchmark for high-growth companies globally." The selection of Tangzhi Pharmaceutical marks its leading position and strong competitiveness in the industry.
2025-01-21
New DNA-encoded chemical library technology to aid drug discovery and development
(Science and Technology Daily) Although researchers have made significant progress in the development of molecular therapies in recent years, the number of newly discovered active substances remains insufficient. Now, the DNA-encoded chemical library (DEL) technology, jointly developed by Harvard University in the US and ETH Zurich in Switzerland, offers a new solution. The technology can automate the synthesis and testing of billions of compounds in a matter of weeks, and can also be used to produce larger drug molecules that will act on targets that are difficult to reach with traditional small molecules.
2024-09-25
